Research & Publications
As a medical student, Dr. Park witnessed the dramatic impact of cancer immunotherapy on refractory late stage metastatic disease at the National Cancer Institute. In Dr. Steven Rosenberg's clinical immunotherapy service, stage 4 cancer patients undergo complete regression of their tumors and remain disease-free for decades. This fascinated Dr. Park and guided her research and career trajectory into surgical oncology with a research emphasis on cancer immunotherapy. After medical school, she returned to the NCI as a surgical oncology and clinical immunotherapy fellow treating these very same patients whose remarkable responses she had first witnessed. During this time, she published 6 papers in basic and translational cancer immunotherapy at the NCI. Dr. Park chose to focus her clinical specialty in breast surgical oncology and completed a fellowship at Duke University. She is currently an Assistant Professor of Surgery at Yale Medical School, Smilow Cancer Hospital, and Director of the Prospective Breast Tumor Biorepository.
Dr. Park has published basic science studies on the topic of improving immunotherapy using novel artificial microRNA constructs against checkpoint inhibitors, and additionally has published on characterizing new immunotherapy targets in a variety of cancers including breast cancer.
Breast; Breast Diseases; Immunotherapy